← Neurocrine Biosciences overview

Neurocrine Biosciences vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Neurocrine Biosciences Inc (NBIX)

Q3 2026
▲3▼1

Neurocrine's Q3: Strong Sales, Pipeline Progress, But Cash Drops

  • Strong Q2 results and raised guidance Neurocrine reported Q2 revenue of $959 million, up 39%, and adjusted EPS of $2.85. Management raised full-year guidance for its key drug INGREZZA to $2.825–$2.875 billion, signaling confidence in continued growth.

    This shows the core business is performing well and management expects further growth, which likely boosted investor confidence.

  • CRENESSITY's rapid growth and expansion CRENESSITY sales surged 247% in Q2 and 400% in the first half. With only 15% of diagnosed patients treated, there's ample room to grow. The drug also expanded into younger children, broadening its market.

    This highlights a major growth driver with significant untapped potential, which could drive future revenue.

  • Pipeline advancements and analyst optimism The obesity drug NBIP-1968 entered Phase 1 testing, and analysts turned bullish, citing a Strong Buy rating and a cheap valuation of about 17 times forward earnings. This suggests upside potential.

    Pipeline progress and positive analyst sentiment can attract investors and support the stock price.

  • Cash decline and competitive threats Cash fell from $2.5 billion to $482 million after the $2.9 billion Soleno acquisition. Additionally, Vertex acquired a rival CAH drug, increasing competition, and pipeline programs remain years from approval.

    These factors raise financial and competitive risks that could weigh on the stock.

August 2026
▲3

Neurocrine's Ingrezza and Crenessity Surge, Obesity Pipeline Advances

  • Q2 Beat and Raised Ingrezza Guidance Neurocrine beat second-quarter expectations with revenue up 39% to $959 million and adjusted earnings of $2.85 per share. Management raised 2026 Ingrezza sales guidance to $2.825-$2.875 billion, signaling confidence in its core drug and lifting investor expectations.

    This is the period's biggest financial catalyst, directly boosting earnings outlook and stock sentiment.

  • Crenessity Sales Surge 400% Crenessity, launched in December 2024 for a rare hormonal disorder, generated $337 million in the first half of 2026, up 400% year over year. Its prescriber base nearly tripled, with only 15% of diagnosed patients on the drug, leaving room for more growth.

    Shows a second drug becoming a major growth driver, reducing reliance on Ingrezza and supporting higher valuation.

  • Obesity Drug Enters Phase 1 Neurocrine started a Phase 1 trial of NBIP-'1968, an experimental obesity drug that targets three hormone receptors. Early-stage testing is a first step toward a potentially large new market, though years of testing remain before any approval.

    Highlights pipeline expansion into the hot obesity space, which can add long-term growth potential.

  • Leadership Changes and Cash Burn Neurocrine appointed a new Chief Business Officer and reappointed its former Chief Medical Officer, bringing continuity and deal-making focus. However, cash fell from $2.5 billion to $482 million after the $2.9 billion Soleno acquisition, and competition looms from Vertex's purchase of a rival CAH drug.

    Balances positive management moves against financial and competitive risks that could pressure the stock.

Latest
▲3

Neurocrine's Ingrezza and Crenessity Surge, Obesity Pipeline Advances

  • Q2 Beat and Raised Ingrezza Guidance Neurocrine beat second-quarter expectations with revenue up 39% to $959 million and adjusted earnings of $2.85 per share. Management raised 2026 Ingrezza sales guidance to $2.825-$2.875 billion, signaling confidence in its core drug and lifting investor expectations.

    This is the period's biggest financial catalyst, directly boosting earnings outlook and stock sentiment.

  • Crenessity Sales Surge 400% Crenessity, launched in December 2024 for a rare hormonal disorder, generated $337 million in the first half of 2026, up 400% year over year. Its prescriber base nearly tripled, with only 15% of diagnosed patients on the drug, leaving room for more growth.

    Shows a second drug becoming a major growth driver, reducing reliance on Ingrezza and supporting higher valuation.

  • Obesity Drug Enters Phase 1 Neurocrine started a Phase 1 trial of NBIP-'1968, an experimental obesity drug that targets three hormone receptors. Early-stage testing is a first step toward a potentially large new market, though years of testing remain before any approval.

    Highlights pipeline expansion into the hot obesity space, which can add long-term growth potential.

  • Leadership Changes and Cash Burn Neurocrine appointed a new Chief Business Officer and reappointed its former Chief Medical Officer, bringing continuity and deal-making focus. However, cash fell from $2.5 billion to $482 million after the $2.9 billion Soleno acquisition, and competition looms from Vertex's purchase of a rival CAH drug.

    Balances positive management moves against financial and competitive risks that could pressure the stock.

July 2026
▲4

Neurocrine's CRENESSITY launch accelerates as Q2 revenue jumps 39%

  • CRENESSITY data broadens and launch surges New ENDO 2026 data showed CRENESSITY improved hormone control, heart and bone health in CAH, and Q2 sales then jumped 247% to $184 million. This tells investors the newest drug is becoming a real second growth engine, not just a promise.

    It is the core new growth story behind the stock's move.

  • Q2 results beat and INGREZZA guidance raised Second-quarter revenue rose 39% to $959 million and adjusted earnings jumped to $2.85 a share. Management raised full-year INGREZZA sales guidance to $2.825-$2.875 billion, signaling the flagship drug keeps growing faster than expected.

    The earnings beat and raised guidance are the period's biggest fresh price driver.

  • Crinecerfont expands toward younger children Neurocrine started a Phase 2 trial of crinecerfont in children aged 3 months to under 4, aiming to widen CRENESSITY's approved use. A larger patient pool means more future sales, though approval is still years away.

    It is a new pipeline expansion that supports long-term growth expectations.

  • Analyst estimates and valuation draw buyers Analysts raised earnings estimates sharply, earning a Zacks Strong Buy, while the stock trades near 17 times forward earnings versus an industry average above 90. Cheap valuation plus rising estimates makes the shares attractive to new investors.

    It explains the money-flow and sentiment side of the rally.

▲4

Neurocrine's CRENESSITY launch accelerates as Q2 revenue jumps 39%

  • CRENESSITY data broadens and launch surges New ENDO 2026 data showed CRENESSITY improved hormone control, heart and bone health in CAH, and Q2 sales then jumped 247% to $184 million. This tells investors the newest drug is becoming a real second growth engine, not just a promise.

    It is the core new growth story behind the stock's move.

  • Q2 results beat and INGREZZA guidance raised Second-quarter revenue rose 39% to $959 million and adjusted earnings jumped to $2.85 a share. Management raised full-year INGREZZA sales guidance to $2.825-$2.875 billion, signaling the flagship drug keeps growing faster than expected.

    The earnings beat and raised guidance are the period's biggest fresh price driver.

  • Crinecerfont expands toward younger children Neurocrine started a Phase 2 trial of crinecerfont in children aged 3 months to under 4, aiming to widen CRENESSITY's approved use. A larger patient pool means more future sales, though approval is still years away.

    It is a new pipeline expansion that supports long-term growth expectations.

  • Analyst estimates and valuation draw buyers Analysts raised earnings estimates sharply, earning a Zacks Strong Buy, while the stock trades near 17 times forward earnings versus an industry average above 90. Cheap valuation plus rising estimates makes the shares attractive to new investors.

    It explains the money-flow and sentiment side of the rally.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.